(UroToday.com) In this presentation, Dr. Emiliano Calvo presented exploratory biomarker data from the ongoing phase 1b study (NCT03150810) of the PARP 1/2 inhibitor pamiparib in combination with low dose temozolomide in solid tumors. The treatment schema is shown below.
(UroToday.com) At the ESMO 2020 virtual annual meeting, Dr. Eleni Efstathiou reviewed several key studies presented during the prostate cancer session. Dr. Efstathiou notes that over the last several decades we have been trying to offer treatment personalization based on the “therapeutic index”: efficacy / adverse events. There are several variables that need to be taken […]
(UroToday.com) Inhibitors of poly (ADP-ribose) polymerase or PARP enzymes are under development in many contexts within oncology. These drugs are thought to be efficacious in the context of impaired DNA damage repair (DDR), especially deficiencies in homologous recombination repair, by further inhibiting PARP-mediated DNA repair mechanisms and thus resulting in tumor cell death. Based on a […]
(UroToday.com) Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor that is approved in adult patients with locally advanced urothelial carcinoma or metastatic urothelial carcinoma and susceptible FGFR3/2 alterations following ≥1 line of platinum-based chemotherapy. Approval of erdafitinib was based on data from the primary analysis of the pivotal BLC2001 trial in adult patients with previously […]
(UroToday.com) Multiple gene expression signatures have been studied for their association with response to anti-PD1 axis therapy in metastatic renal cell carcinoma, but the utility of these signatures for predicting response to non-PD1 axis therapy is unknown. In this poster, Dr. Frede Donskov and colleagues explored the correlation of four specific gene expression signatures (T-cell inflamed gene […]
(UroToday.com) Urothelial carcinoma has a substantial impact on patient qualify of life. Patients may experience a multitude of disease-related symptoms, including pain, urinary frequency, physical changes, and mental health issues, with all affect quality of life. Additionally, treatment side effects of chemotherapy have been shown to reduce the quality of life in patients with advanced […]
(UroToday.com) The TRACERx (TRAcking Cancer Evolution through therapy (Rx)) consortium aims to utilize cutting edge biologic techniques and analysis to uncover mechanisms of cancer evolution as well as explore intratumoral heterogeneity and its association with therapy response. In a 2018 paper, the consortium published genomic data from 1,206 primary tumor biopsies from 101 patients with clear […]
(UroToday.com) At this year’s European Society of Medical Oncology (ESMO) 2020 Virtual Congress, following two abstracts assessing the role of metformin and local prostate-directed therapy in patients with newly diagnosed, hormone-sensitive metastatic prostate cancer, Dr. Noel Clarke provided an invited discussion of these data.
(UroToday.com) Patients with newly-diagnosed metastatic hormone-sensitive prostate cancer have a plethora of treatment options available. In addition to a number of systemic therapies, data from the HORRAD trial and STAMPEDE-RT have demonstrated a survival benefit to the addition of local, prostate-directed radiotherapy for men with low-volume metastatic disease.
(UroToday.com) Metformin is a biguanide agent which is commonly used in the first-line treatment of patients with type 2 diabetes. For many years, there has been an interest in its potential anti-cancer properties, particularly in prostate cancer. In observational studies, there has been a demonstrated association between the use of metformin and improved overall survival and […]
